A new bladder cancer drug given directly into the bladder
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new drug, SHR-2005, given directly into the bladder through a catheter. It is for people with intermediate- or high-risk bladder cancer that hasn't spread into the muscle, and aims to see if it is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have intermediate- or high-risk non-muscle invasive bladder cancer (confirmed by biopsy).
- You are in good enough health to do daily activities (ECOG 0 or 1).
- Your doctor expects you to live at least 2 more years.
- You haven't had bladder surgery (like TURBT) in the last 2 weeks.
- You haven't taken certain immunotherapy drugs (like OX40 or CD137 agonists) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two investigational drugs given together to treat high-risk non-muscle invasive bladder cancer that cannot be completely removed with standard surgery. The goal is to see if this combination can help control the cancer and avoid the need for bladder removal.
This study tests a new drug, RAG-01, given alone or with chemotherapy, for people with a type of bladder cancer that hasn't spread into the muscle. The goal is to see if it can help treat the cancer and if it's safe.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, for people with muscle-invasive bladder cancer that hasn't spread. The goal is to see if this treatment can help control the cancer.
This trial tests whether a new bladder cancer drug (SHR-1501) works alone or combined with BCG, and compares options with another drug (SHR-1316), in people with high-risk non–muscle-invasive bladder cancer. It may help reduce cancer coming back and improve control of the disease.
This trial tests a new drug called SHR-A2102, which is a type of targeted therapy (an antibody-drug conjugate) for advanced urothelial carcinoma (bladder cancer). It may help if your cancer has not responded to standard treatments or if you are starting treatment for advanced disease.
Hear when a new Intermediate and High-risk Non-muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.